{"analyses":[{"ciLowerLimit":"0.35","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","estimateComment":"A hazard ratio \\< 1 favours osimertinib","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.088","paramType":"Hazard Ratio (HR)","paramValue":"0.62","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA - Not calculated as insufficient number of events to enable the upper limit of 95% confidence interval to be calculated","groupId":"OG000","lowerLimit":"44.42","upperLimit":"NA","value":"48.20"},{"comment":"NA - Not calculated as insufficient number of events to enable the upper limit of 95% confidence interval to be calculated","groupId":"OG001","lowerLimit":"28.22","upperLimit":"NA","value":"47.38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Time from randomisation to the earliest progression event following first objective disease progression, subsequent to the first subsequent therapy, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for first 48 weeks, then every 12 weeks. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Second Progression-free Survival (PFS2)","type":"SECONDARY","unitOfMeasure":"Months"}